Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of aTTP
Retrospective Analysis of the Efficiency of Caplacizumab in the Treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP)- REACT-2020
University of Cologne
350 participants
Mar 25, 2021
OBSERVATIONAL
Conditions
Summary
The objective of this national, prospective, multi-centre observational study is to describe the prescription rational and practice in Germany, confirm the efficacy of caplacizumab in a real-world setting, and identify predicting factors in iTTP-patients with regard to persistent autoimmune activity, therapy guidance and risk of complications. The rational is to develop new treatment algorithms that optimize overall patient outcome and reduce treatment cost.
Eligibility
Inclusion Criteria4
- Confirmed diagnosis of an acute episode of acquired thrombotic thrombocytopenic purpura
- Treatment with at least one single dose of caplacizumab (10 mg i.v. or s.c.)
- Male or female patients ≥ 18 years of age
- signed written informed consent
Exclusion Criteria2
- Hereditary thrombotic thrombocytopenic purpura
- disability to give informed consent
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Intervention with Cablivi® take place outside of the study
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04985318